| Dr Brian Christopher Thomas, MD | |
|
2471 Helton Dr, Florence, AL 35630-1067 | |
| (256) 765-2000 | |
| (256) 765-2001 |
| Full Name | Dr Brian Christopher Thomas |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 25 Years |
| Location | 2471 Helton Dr, Florence, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508837394 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Forefront Dermatology | 3779471701 | 474 |
News Archive
Research highlights more must be done to improve stroke care for First Nations People, with current outcomes failing to meet national standards.
U.S. seniors forced to pay full price for their medications while in Medicare's so-called donut hole didn't suffer more heart attacks or deaths as a result, in a new study.
Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today presented positive data from a multi-centre prospective evaluation of MycAssay Pneumocystis, the Company's CE marked diagnostic product for detection of Pneumocystis DNA in respiratory samples.
White House Drug Control Policy Director Michael Botticelli has awarded Boston University School of Medicine's Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program a 2014 National High Intensity Drug Trafficking Area (HIDTA) award for Outstanding Prevention Effort.
› Verified 2 days ago
| Entity Name | Forefront Dermatology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366936759 PECOS PAC ID: 3779471701 Enrollment ID: O20180911002840 |
News Archive
Research highlights more must be done to improve stroke care for First Nations People, with current outcomes failing to meet national standards.
U.S. seniors forced to pay full price for their medications while in Medicare's so-called donut hole didn't suffer more heart attacks or deaths as a result, in a new study.
Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today presented positive data from a multi-centre prospective evaluation of MycAssay Pneumocystis, the Company's CE marked diagnostic product for detection of Pneumocystis DNA in respiratory samples.
White House Drug Control Policy Director Michael Botticelli has awarded Boston University School of Medicine's Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program a 2014 National High Intensity Drug Trafficking Area (HIDTA) award for Outstanding Prevention Effort.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian Christopher Thomas, MD 801 York St, Manitowoc, WI 54220-4630 Ph: (920) 663-9008 | Dr Brian Christopher Thomas, MD 2471 Helton Dr, Florence, AL 35630-1067 Ph: (256) 765-2000 |
News Archive
Research highlights more must be done to improve stroke care for First Nations People, with current outcomes failing to meet national standards.
U.S. seniors forced to pay full price for their medications while in Medicare's so-called donut hole didn't suffer more heart attacks or deaths as a result, in a new study.
Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today presented positive data from a multi-centre prospective evaluation of MycAssay Pneumocystis, the Company's CE marked diagnostic product for detection of Pneumocystis DNA in respiratory samples.
White House Drug Control Policy Director Michael Botticelli has awarded Boston University School of Medicine's Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program a 2014 National High Intensity Drug Trafficking Area (HIDTA) award for Outstanding Prevention Effort.
› Verified 2 days ago
Dr. Joseph Michael Webb, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2471 Helton Dr, Florence, AL 35630 Phone: 256-765-2000 Fax: 256-765-2001 | |
Dr. Joseph Wayne Hanson Sr., M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2471 Helton Dr, Florence, AL 35630 Phone: 256-765-2000 Fax: 256-765-2001 | |
Dr. Ann Bennett, M D Dermatology Medicare: Not Enrolled in Medicare Practice Location: 216 Marengo St, Suite D, Florence, AL 35630 Phone: 256-767-1017 Fax: 256-767-1018 |